Maurizio Scaltriti

Human Oncology & Pathogenesis Program (HOPP), Memorial Sloan Kettering Cancer Center

Affiliated withMemorial Sloan Kettering Cancer Center

Research Area

Biography

Maurizio Scaltriti has not added Biography.
If you are Maurizio Scaltriti and would like to personalize this page please email our Author Liaison for assistance.

JoVE Journal Publications

ArticleTotal : 1	Year
Publication title Cited by 2	2020

Other Publications

Article	Year
Inhibitors of HSP90 block p95-HER2 signaling in Trastuzumab-resistant tumors and suppress their growth. Oncogene\| PubMed ID: 19855434	2010
Clinical benefit of lapatinib-based therapy in patients with human epidermal growth factor receptor 2-positive breast tumors coexpressing the truncated p95HER2 receptor. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 20406840	2010
AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. Cancer cell\| PubMed ID: 21215704	2011
Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients. Proceedings of the National Academy of Sciences of the United States of America\| PubMed ID: 21321214	2011
mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling. Cancer discovery\| PubMed ID: 22140653	2011
RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer. The Journal of clinical investigation\| PubMed ID: 23635776	2013
mTORC1 inhibition is required for sensitivity to PI3K p110α inhibitors in PIK3CA-mutant breast cancer. Science translational medicine\| PubMed ID: 23903756	2013
Targeting the MUC1-C oncoprotein downregulates HER2 activation and abrogates trastuzumab resistance in breast cancer cells. Oncogene\| PubMed ID: 23912457	2014
Clinical response to a lapatinib-based therapy for a Li-Fraumeni syndrome patient with a novel HER2V659E mutation. Cancer discovery\| PubMed ID: 23950206	2013
Potential biomarkers of long-term benefit from single-agent trastuzumab or lapatinib in HER2-positive metastatic breast cancer. Molecular oncology\| PubMed ID: 24075779	2014
Evaluation and clinical analyses of downstream targets of the Akt inhibitor GDC-0068. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 24141624	2013
Antagonism of EGFR and HER3 enhances the response to inhibitors of the PI3K-Akt pathway in triple-negative breast cancer. Science signaling\| PubMed ID: 24667376	2014
Effect of p95HER2/611CTF on the response to trastuzumab and chemotherapy. Journal of the National Cancer Institute\| PubMed ID: 25253614	2014
Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor. Nature\| PubMed ID: 25409150	2015
Therapeutic antibodies in breast cancer. Seminars in oncology\| PubMed ID: 25440604	2014
High HER2 expression correlates with response to the combination of lapatinib and trastuzumab. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 25467182	2015
AXL mediates resistance to PI3Kα inhibition by activating the EGFR/PKC/mTOR axis in head and neck and esophageal squamous cell carcinomas. Cancer cell\| PubMed ID: 25873175	2015
PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer. Science translational medicine\| PubMed ID: 25877889	2015
Quantification of HER family receptors in breast cancer. Breast cancer research : BCR\| PubMed ID: 25887735	2015
MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 26272063	2015
High HER2 protein levels correlate with increased survival in breast cancer patients treated with anti-HER2 therapy. Molecular oncology\| PubMed ID: 26422389	2016
Taselisib (GDC-0032), a Potent β-Sparing Small Molecule Inhibitor of PI3K, Radiosensitizes Head and Neck Squamous Carcinomas Containing Activating PIK3CA Alterations. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 26589432	2016
AKT signaling in ERBB2-amplified breast cancer. Pharmacology & therapeutics\| PubMed ID: 26645663	2016
Molecular Pathways: AXL, a Membrane Receptor Mediator of Resistance to Therapy. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 26763248	2016
Pten loss promotes MAPK pathway dependency in HER2/neu breast carcinomas. Proceedings of the National Academy of Sciences of the United States of America\| PubMed ID: 26929372	2016
Somatic PIK3CA mutations as a driver of sporadic venous malformations. Science translational medicine\| PubMed ID: 27030594	2016
Differential Receptor Tyrosine Kinase PET Imaging for Therapeutic Guidance. Journal of nuclear medicine : official publication, Society of Nuclear Medicine\| PubMed ID: 27081168	2016
Rationale-based therapeutic combinations with PI3K inhibitors in cancer treatment. Molecular & cellular oncology\| PubMed ID: 27308344	2014
P-selectin is a nanotherapeutic delivery target in the tumor microenvironment. Science translational medicine\| PubMed ID: 27358497	2016
PDK1-SGK1 Signaling Sustains AKT-Independent mTORC1 Activation and Confers Resistance to PI3Kα Inhibition. Cancer cell\| PubMed ID: 27451907	2016
Stratification and therapeutic potential of PML in metastatic breast cancer. Nature communications\| PubMed ID: 27553708	2016
Systematic Functional Characterization of Resistance to PI3K Inhibition in Breast Cancer. Cancer discovery\| PubMed ID: 27604488	2016
The emerging role of serum/glucocorticoid-regulated kinases in cancer. Cell cycle (Georgetown, Tex.)\| PubMed ID: 27636373	2017
PIM1 kinase regulates cell death, tumor growth and chemotherapy response in triple-negative breast cancer. Nature medicine\| PubMed ID: 27775704	2016
CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer. Cell reports\| PubMed ID: 27880910	2016
Tumour-specific PI3K inhibition via nanoparticle-targeted delivery in head and neck squamous cell carcinoma. Nature communications\| PubMed ID: 28194032	2017
PI3K pathway regulates ER-dependent transcription in breast cancer through the epigenetic regulator KMT2D. Science (New York, N.Y.)\| PubMed ID: 28336670	2017
Overcoming resistance to HER2-targeted therapy with a novel HER2/CD3 bispecific antibody. Oncoimmunology\| PubMed ID: 28405494	2017
A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion-Positive Solid Tumors. Cancer discovery\| PubMed ID: 28578312	2017
Somatic chromosomal engineering identifies BCAN-NTRK1 as a potent glioma driver and therapeutic target. Nature communications\| PubMed ID: 28695888	2017
Genotyping tumour DNA in cerebrospinal fluid and plasma of a HER2-positive breast cancer patient with brain metastases. ESMO open\| PubMed ID: 29067216	2017
Genetic Predictors of Response to Systemic Therapy in Esophagogastric Cancer. Cancer discovery\| PubMed ID: 29122777	2018
The prognostic value of PI3K mutational status in breast cancer: A meta-analysis. Journal of cellular biochemistry\| PubMed ID: 29345357	2018
HER kinase inhibition in patients with HER2- and HER3-mutant cancers. Nature\| PubMed ID: 29420467	2018
Coamplification of protects -amplified breast cancers from targeted therapy. Proceedings of the National Academy of Sciences of the United States of America\| PubMed ID: 29476008	2018
A network modeling approach to elucidate drug resistance mechanisms and predict combinatorial drug treatments in breast cancer. Cancer convergence\| PubMed ID: 29623959	2017
Oncogenic TRK fusions are amenable to inhibition in hematologic malignancies. The Journal of clinical investigation\| PubMed ID: 29920189	2018
Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology\| PubMed ID: 29989854	2018
The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers. Cancer cell\| PubMed ID: 30205045	2018
p95HER2-T cell bispecific antibody for breast cancer treatment. Science translational medicine\| PubMed ID: 30282693	2018
Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2). Science signaling\| PubMed ID: 30301790	2018
NTRK fusion-positive cancers and TRK inhibitor therapy. Nature reviews. Clinical oncology\| PubMed ID: 30333516	2018
and Amplifications Determine Response to HER2 Inhibition in -Amplified Esophagogastric Cancer. Cancer discovery\| PubMed ID: 30463996	2019
Loss of the FAT1 Tumor Suppressor Promotes Resistance to CDK4/6 Inhibitors via the Hippo Pathway. Cancer cell\| PubMed ID: 30537512	2018
Colorectal Carcinomas Containing Hypermethylated MLH1 Promoter and Wild-Type BRAF/KRAS Are Enriched for Targetable Kinase Fusions. Cancer research\| PubMed ID: 30643016	2019
MET activation confers resistance to cetuximab, and prevents HER2 and HER3 upregulation in head and neck cancer. International journal of cancer\| PubMed ID: 30694565	2019
Author Correction: HER kinase inhibition in patients with HER2- and HER3-mutant cancers. Nature\| PubMed ID: 30755741	2019
PI3K Inhibition Activates SGK1 via a Feedback Loop to Promote Chromatin-Based Regulation of ER-Dependent Gene Expression. Cell reports\| PubMed ID: 30943409	2019
Prevalence and role of HER2 mutations in cancer. Pharmacology & therapeutics\| PubMed ID: 30951733	2019
Solid pseudopapillary neoplasms of the pancreas are dependent on the Wnt pathway. Molecular oncology\| PubMed ID: 30972907	2019
Cell-free DNA analysis in healthy individuals by next-generation sequencing: a proof of concept and technical validation study. Cell death & disease\| PubMed ID: 31296838	2019
Resistance to TRK inhibition mediated by convergent MAPK pathway activation. Nature medicine\| PubMed ID: 31406350	2019
Double mutations in cis increase oncogenicity and sensitivity to PI3Kα inhibitors. Science (New York, N.Y.)\| PubMed ID: 31699932	2019
Efficacy and Determinants of Response to HER Kinase Inhibition in HER2-Mutant Metastatic Breast Cancer. Cancer discovery\| PubMed ID: 31806627	2019
TRK Fusions are Enriched in Cancers with Uncommon Histologies and the Absence of Canonical Driver Mutations. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 31871300	2019